Evaluation on clot buster activity of staphylokinase from Staphylococcus sp.

Cardiovasc Hematol Agents Med Chem

Environmental Biotechnology Division, School of Biosciences and Technology, Vellore Institute of Technology University, Vellore, Tamil Nadu, India.

Published: September 2015

Thrombolytic agents play a major role in the treatment of cardiovascular diseases. Streptokinase is the prominently commercialized thrombolytic drug used for the treatment of cardiovascular diseases. The later studies on staphylokinase (SaK) showed promising results as an alternative fibrinolytic drug. The present study explores the isolation, production and purification of SaK producing Staphylococcus sp. from milk samples. The potent isolate MSA4 of Staphylococcus sp. was selected for production and purification of SaK. The total activity and specific activity of purified staphylokinase was found to be 1266 IU mL(-1) and 815.5 IU mg(-1), respectively. The partially purified enzyme was lysed the euglobulin clot completely within 18 h of incubation and the purified enzyme showed 79% of blood clot lysis activity.

Download full-text PDF

Source
http://dx.doi.org/10.2174/1871525712666141106102809DOI Listing

Publication Analysis

Top Keywords

treatment cardiovascular
8
cardiovascular diseases
8
production purification
8
purification sak
8
purified enzyme
8
evaluation clot
4
clot buster
4
activity
4
buster activity
4
activity staphylokinase
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!